General practitioners' adherence to chronic heart failure guidelines regarding medication: the GP-HF study

Area of Science:

• Cardiology
• General Practice
• Pharmacotherapy

Background:

• Adherence to chronic heart failure (HF) pharmacotherapy guidelines improves patient prognosis.
• General practitioners (GPs) manage the majority of HF patients, yet their guideline adherence and prescribing rationales are not well-documented.

Purpose of the Study:

• To assess current guideline adherence for HF pharmacotherapy among GPs.
• To identify factors influencing GPs' prescribing decisions for HF medications.
• To evaluate the impact of addressing documentation deficits and contraindications on guideline adherence.

Main Methods:

• A three-stage study involving analysis of patient records (Stage I), GP interviews (Stage II), and patient interviews (Stage III).
• Quantified prescription rates and doses of ACE-inhibitors/angiotensin receptor blockers (ACEIs/ARBs), beta blockers (BBs), and mineralocorticoid receptor antagonists (MRAs).
• Calculated a guideline adherence indicator (GAI-3) and assessed reasons for non-adherence.

Main Results:

• Initial adherence: 76% ACEIs/ARBs, 73% BBs, 18% MRAs; GAI-3 was 22%.
• After addressing documentation and contraindications: 87% ACEIs/ARBs, 84% BBs; GAI-3 increased to 56%.
• MRAs remained underprescribed despite frequent contraindications; GPs lacked awareness of MRA value and target doses for other drugs. Patient compliance was generally good, with 11% discontinuing medication.

Conclusions:

• GP guideline adherence for HF pharmacotherapy is higher than previously suggested.
• Further improvements can be achieved by emphasizing MRAs as a key drug class and reinforcing the importance of reaching target doses.
• Awareness of MRA's prognostic value and adherence to target doses for ACEIs/ARBs and BBs are crucial for optimizing HF management.